Literature DB >> 24891018

Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs.

Sarah E Holden1, Christian A Bannister, Craig J Currie.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24891018     DOI： 10.1007/s00125-014-3281-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  3 in total

1.  Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment.

Authors:  Kristina Ranc; Marit E Jørgensen; Søren Friis; Bendix Carstensen
Journal:  Diabetologia       Date:  2014-03-15       Impact factor: 10.122

2.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Authors:  Mahvash Zakikhani; Ryan Dowling; I George Fantus; Nahum Sonenberg; Michael Pollak
Journal:  Cancer Res       Date:  2006-10-23       Impact factor: 12.701

3.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Authors:  C J Currie; C D Poole; E A M Gale
Journal:  Diabetologia       Date:  2009-07-02       Impact factor: 10.122
  3 in total
  1 in total

1.  Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs. Reply to Holden SE, Bannister CA, Currie CJ [letter].

Authors:  Kristina Ranc; Marit E Jørgensen; Søren Friis; Bendix Carstensen
Journal:  Diabetologia       Date:  2014-07-18       Impact factor: 10.122
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.